These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 10682228)

  • 1. Diurnal motor variations to repeated doses of levodopa in Parkinson's disease.
    Bonuccelli U; Del Dotto P; Lucetti C; Petrozzi L; Bernardini S; Gambaccini G; Rossi G; Piccini P
    Clin Neuropharmacol; 2000; 23(1):28-33. PubMed ID: 10682228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diurnal worsening in Parkinson patients treated with levodopa].
    Piccini P; Del Dotto P; Pardini C; D'Antonio P; Rossi G; Bonuccelli U
    Riv Neurol; 1991; 61(6):219-24. PubMed ID: 1813974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
    Nutt JG; Carter JH; Carlson NE
    Arch Neurol; 2007 Mar; 64(3):319-23. PubMed ID: 17353373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
    Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I
    J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.
    Nutt JG; Carter JH; Lea ES; Woodward WR
    Mov Disord; 1997 May; 12(3):285-92. PubMed ID: 9159720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease.
    Napolitano A; Del Dotto P; Petrozzi L; Dell'Agnello G; Bellini G; Gambaccini G; Bonuccelli U
    Clin Neuropharmacol; 1999; 22(1):24-9. PubMed ID: 10047930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetic profile of the "first ever" oral dose of levodopa in de novo patients with Parkinson's disease.
    Djaldetti R; Rosmarin V; Ziv I; Melamed E
    Clin Neuropharmacol; 2001; 24(2):95-8. PubMed ID: 11307044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.
    Contin M; Martinelli P; Mochi M; Riva R; Albani F; Baruzzi A
    Mov Disord; 2005 Jun; 20(6):734-9. PubMed ID: 15747357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
    Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC
    Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study.
    Djaldetti R; Giladi N; Hassin-Baer S; Shabtai H; Melamed E
    Clin Neuropharmacol; 2003; 26(6):322-6. PubMed ID: 14646613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
    Stocchi F; Rabey JM
    Eur J Neurol; 2011 Dec; 18(12):1373-8. PubMed ID: 21895884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.
    Hauser RA; Ellenbogen AL; Metman LV; Hsu A; O'Connell MJ; Modi NB; Yao HM; Kell SH; Gupta SK
    Mov Disord; 2011 Oct; 26(12):2246-52. PubMed ID: 21755537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of soybean ingestion on pharmacokinetics of levodopa and motor symptoms of Parkinson's disease--In relation to the effects of Mucuna pruriens.
    Nagashima Y; Kondo T; Sakata M; Koh J; Ito H
    J Neurol Sci; 2016 Feb; 361():229-34. PubMed ID: 26810548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson's disease.
    Del Dotto P; Colzi A; Musatti E; Strolin Benedetti M; Persiani S; Fariello R; Bonuccelli U
    Clin Neuropharmacol; 1997 Oct; 20(5):455-65. PubMed ID: 9331523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessment.
    Senek M; Aquilonius SM; Askmark H; Bergquist F; Constantinescu R; Ericsson A; Lycke S; Medvedev A; Memedi M; Ohlsson F; Spira J; Westin J; Nyholm D
    Eur J Clin Pharmacol; 2017 May; 73(5):563-571. PubMed ID: 28101657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa and 3-O-methyldopa plasma levels in parkinsonian patients with stable and fluctuating motor response.
    Luquin MR; Vaamonde J; Obeso JA
    Clin Neuropharmacol; 1989 Feb; 12(1):46-54. PubMed ID: 2713867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinical, pharmacologic, and polysomnographic study of sleep benefit in Parkinson's disease.
    Högl BE; Gómez-Arévalo G; García S; Scipioni O; Rubio M; Blanco M; Gershanik OS
    Neurology; 1998 May; 50(5):1332-9. PubMed ID: 9595983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.